Aurimic Ear Drops And Cutaneous Suspension For Dogs And Cats
Revised: July 2015
NAME OF THE VETERINARY MEDICINAL PRODUCT
Mitexeardrops andcutaneous suspensionfordogs and cats
(AT, DE, EE,EL, ES, FR,HR,IT, LT, LV,PT
Saniotic vet. eardropsandcutaneoussuspensionfordogs and cats
(DK, FI,IS, NO, SE
Aurimic eardrops and cutaneoussuspension fordogsand cats
(BE, BG, IE, NL, RO, UK
Orilan eardropsand cutaneous suspensionfordogs and cats
(CZ, HU, PL, SK)
QUALITATIVE AND QUANTITATIVE COMPOSITION
Miconazolenitrate 23.0 mg
(equivalentto19.98 mg miconazole)
Prednisoloneacetate 5.0 mg
Polymyxin Bsulfate 0.5293mg
(equivalentto5500 IUpolymyxin Bsulfate)
Forthe fulllistofexcipients, seesection6.1
Dogs and cats.
Indications for use, specifying the target species
Forthe treatmentofotitis externa andsmalllocalisedsuperficialskininfectionsindogs and cats caused byinfections with the followingmiconazole and polymyxin Bsensitive bacteriaandfungi:
Yeasts and fungi
TreatmentofOtodectes cynotis infestations wherethere isconcurrentinfectionwith miconazoleand polymyxin Bsensitive pathogens.
in case of hypersensitivity to the active substances of the veterinary medicinal product, as well as to other corticosteroids, to other azole antifungal agents, or to the excipients
in animals with perforated ear drums
in animals, where resistance of causative agents to polymyxin B and/or miconazole is known
on the mammary glands of lactating bitches and queens
Special warnings for each target species
Bacterialand fungalotitisis often secondaryinnature.The underlyingcause should beidentified and treated.
Special precautions for use
Special precautions for usein animals
Use ofthe productshould be based on microbiologicalsamplingandsusceptibilitytestingofthe bacteria and/orfungi isolated fromthe animal. Ifthis is notpossible,therapyshould be based upon
Systemic corticosteroid effectsare possible,especiallywhen the productis used underan occlusive dressing, on extensive skinlesions,with increased skinbloodflow, oriftheproductis ingestedby licking.
Oralingestion ofthe productbytreated animals oranimals havingcontactwithtreated animals should be avoided.
Special precautions tobetakenbythe person administeringthe veterinarymedicinal producttoanimals
Peoplewith known hypersensitivityto prednisolone, polymyxin Bormiconazoleshould avoid contact withthe veterinarymedicinalproduct.
Avoid contactwithskinoreyes. In case ofaccidentalspillage, skin oreyes shouldbe rinsed immediatelywith plentyofwater. Always wearsingleuse disposable gloves whenapplyingthe veterinarymedicinalproductto animals. Wash handsafteruse.
In case ofaccidentalingestion, seekmedicaladviceimmediatelyandshowthe leafletorthe labelto the physician.
Adverse reactions (frequency and seriousness)
Use ofthis veterinarymedicinalproduct may veryrarelybe associatedwiththe occurrence ofdeafness (especiallyin olderdogs),in this casetreatmentshouldbe discontinued.
Prolonged and extensive use oftopicalcorticosteroid preparations is known totriggerlocaland systemic effects,includingsuppression ofadrenalfunction,thinningofthe epidermis and delayed healing.
Use during pregnancy and lactation
Thesafetyoftheproducthas notbeen assessed duringpregnancyandlactation.
Absorptionofmiconazole,polymyxin Band prednisolone through the skin beinglow, noteratogenic/ embryotoxic/foetotoxic andmaternotoxiceffectsareexpected in dogs andcats. Oralingestion ofthe active substances bytreatedanimals whengroomingcan possiblyoccurand appearance ofthe active ingredients inblood and milkcan beexpected.
Use onlyaccordinglyto thebenefit/riskassessmentbythe veterinarian.
Interaction with other medicinal products and other forms of interaction
Amounts to be administered and administration route
Shake wellbefore use.
Atthebeginningoftreatment, hairsurroundingorcoveringthelesions mustbeclipped;this should be repeated duringtreatmentifnecessary.
Infectionsoftheexternalauditorycanal (otitis externa):
Cleantheexternalearcanalandauricleand place 5 drops ofthe veterinarymedicinalproductinto the externalauditorycanaltwice a day. Massage the earand theauditorycanal thoroughlyto ensure
properdistribution ofthe active substances, butgentlyenough to avoidcausingpain tothe animal.
Treatmentshould becontinued withoutinterruption untilafewdays aftercomplete disappearance of the clinicalsymptoms, atleastfor7-10 days up to 14days.
Where concurrentearmite(Otodectes cynotis)infestation is present,consideration should be given to treatingbothears even ifinfestationisonlyapparentinone ear. Instill5drops twice dailyfor14 days.
Applya fewdrops ofthe veterinarymedicinalproduct to theskinlesionsto betreated twice adayand rub well.
Treatmentshould becontinued withoutinterruption untilafewdays aftercomplete disappearance of the clinicalsymptoms, up to 14 days.
In some persistentcases (earorskin infections), treatmentmayneed to becontinuedfor2to 3 weeks. In cases whereprolonged treatmentis necessaryrepeated clinicalexaminationsincludinga re- assessmentofthediagnosisarerequired.
Overdose (symptoms, emergency procedures, antidotes), if necessary
No othersymptoms thanthose mentionedin section 4.6 areexpected.
Pharmacotherapeutic group:Otologicals, corticosteroids and anti-infectives in combination ATCvetcode:QS02CA01
Miconazolebelongs tothegroup of N-substitutedimidazole derivatives andinhibits ergosterol de novosynthesis. Ergosterolis anessentialmembranelipid and mustbe synthesised byfungi. Ergosteroldeficiencyimpedes numerous membrane functions,eventuallyleadingto the cell’sdeath. Thespectrumofactivitiescovers nearlyallfungiand yeasts ofrelevanceto veterinarymedicine as wellasGram-positive bacteria. Practicallyno developmentofresistance has beenreported. Miconazolehasa fungistatic mode ofaction, buthighconcentrationsare also observed to produce fungicidaleffects.
Polymyxin Bbelongs tothe polypeptide antibiotics whichareisolatedfrombacteria.Itisonlyactive againstGram-negative bacteria.Thedevelopmentofresistance is chromosomalinnatureand the developmentofresistantGram-negative pathogensisarelativelyrareevent. However, allProteus speciesshare anaturalresistance topolymyxinB.
Polymyxin Bbindsto phospholipids in the cytoplasmic membranetodisturb membrane permeability. Thisresults inautolysis ofthe bacteria, thus achievingbactericidalactivity.
Prednisoloneisa syntheticcorticosteroidand is used forits anti-inflammatory, anti-pruritic, anti- exudative andanti-proliferative effects.The anti-inflammatoryactivityofprednisolone acetateresults fromreduction ofthepermeabilityofcapillaries,improved bloodflowand inhibition offibroblast action.
Theexactmechanismofthe acaricidaleffectis unclear. Itis assumed thatthe mites are suffocated or immobilised bythe oilyexcipients.
Followingtopicalapplication ofpolymyxinB, there isvirtuallyno absorption ofthe compound through intactskin and mucous membranes, butsignificantabsorption viawounds.
Aftertopicalapplication ofmiconazole, thereis virtuallyno absorption ofthecompound through intactskinormucous membranes.
Whenappliedtopicallyto intactskin, prednisolone is subjectto limitedand delayed absorption. Greaterabsorptionofprednisoloneshould beexpectedin casesofcompromisedskin barrier function
(e.g. skin lesions).
List of excipients
Silica,colloidalanhydrous Paraffin liquid
Shelf-life ofthe veterinarymedicinalproductaspackaged forsale:2 years
Shelf-life afterfirstopeningthe immediatepackaging:3 months
Special precautions for storage
Do notstore above 30°C.
Afterfirstopeningdo notstore above 25°C.
Nature and composition of immediate packaging
Droppercontainerofwhite,opaque LDPEwith white,opaque HDPEscrewcap. Packsize:1 x20 ml
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Anyunused veterinarymedicinalproductorwastematerialsderived fromsuch veterinarymedicinal productshould be disposedofinaccordance withlocalrequirements.
MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER
DATE OF FIRST AUTHORISATION
05 March 2015
DATE OF REVISION OF THE TEXT
Page 12 of 12